The first full trading week of the second half opened with a heavy slate of bullish sell-side calls that spanned AI silicon, regional banks, life insurance, independent power, and eye-care medtech. Chair Kevin Warsh's June 17 FOMC held policy at 3.50%–3.75% and CME FedWatch still assigns roughly an 80% probability to zero cuts this year, so idiosyncratic catalysts continue to dominate the tape. All five names below picked up Buy upgrades, Buy initiations, or notable Buy-side price-target hikes on July 6.
Advanced Micro Devices (AMD) — Goldman Sachs takes the target to $640 on server CPU momentum
AMD is the merchant-silicon leader in x86 server CPUs, PC CPUs, and AI accelerators, with the MI400 launch positioned as the next leg of the data-center story. On July 6, Goldman Sachs analyst James Schneider reiterated Buy and raised his target from $450 to $640, writing that upside is driven "mainly by server CPUs" and a "favorable setup" from continued server-CPU strength. Cantor Fitzgerald's C.J. Muse holds Overweight $700, UBS's Timothy Arcuri Buy $670, Barclays's Tom O'Malley Overweight $665, and Wells Fargo's Aaron Rakers Overweight $615.
Shares closed at $552.05 on July 6, up 6.61%, with a market cap of $900.2 billion and a trailing P/E of 120.53. The 52-week range is $133.50 to $584.73. The consensus rating is Strong Buy, with 13 of 13 covering analysts bullish, an average target of $604.54, a median of $600, a high of $700, and a low of $500. The framing is a Street-favorite AI silicon name pushing on its 52-week high where every covering analyst tracked has a bullish rating.
Risks: Nvidia's software-and-networking moat in accelerated compute remains formidable; hyperscaler in-house silicon programs at Amazon, Google, and Microsoft can pressure merchant demand; PC end-market weakness could weigh on the client segment; and the current multiple leaves little room for execution slips.
Flagstar Financial (FLG) — TD Cowen sees earnings inflection ahead
Flagstar Financial, the successor to New York Community Bancorp, is a mid-cap commercial bank still working through a multi-year turnaround under CEO Joseph Otting. On July 6, TD Cowen analyst Janet Lee upgraded the stock from Hold to Buy and raised her target from $15 to $18, citing "improving visibility into earnings acceleration and sustained profitability gains" and calling rent-regulated multifamily risk "manageable." Citigroup's Benjamin Gerlinger sits at Buy $18, Piper Sandler's Manuel Navas at Overweight $17.50, DA Davidson's Peter Winter at Buy $17, and Barclays's Jared Shaw at Overweight $16.
Shares closed at $14.84 on July 6, up 1.71%, with a market cap of $6.2 billion. The company is not yet at a normalized trailing profit, so a trailing P/E is not meaningful. The 52-week range is $10.57 to $15.37. The consensus rating is Buy, with 7 of 10 analysts bullish, an average target of $16.75, a median of $17, a high of $18, and a low of $15. The framing is a turnaround bank pressing on its 52-week high as another Street shop signals that the credit and earnings inflection is finally becoming visible.
Risks: continued deterioration in New York rent-regulated multifamily credit; slower-than-expected commercial-loan growth as the bank shrinks its balance sheet; regulatory overhang under Category IV bank standards; and execution risk on the deposit-mix rebuild.
Lincoln National (LNC) — Barclays sees the capital-building phase ending
Lincoln National is a mid-cap U.S. life-insurance and annuities carrier that has spent the last several years rebuilding capital and derisking its variable-annuity book. On July 6, Barclays analyst Alex Scott upgraded the stock from Equal-Weight to Overweight and raised his target from $42 to $45, writing that Lincoln "is nearing the end of its capital-building process and may soon be able to redeploy capital through share repurchases." Morgan Stanley's Bob Huang holds Overweight $40, Wells Fargo's Wesley Carmichael Overweight $44, Mizuho's Yaron Kinar Outperform $48, and KBW's Ryan Krueger Outperform $44.
Shares closed at $38.39 on July 6, up 3.76%, with a market cap of $7.3 billion, a trailing P/E of 4.64, and a dividend yield near 5%. The 52-week range is $32.18 to $46.82. The consensus rating is Buy, with 5 of 10 analysts bullish, an average target of $42.10, a median of $42, a high of $48, and a low of $37. The framing is a mid-cap life insurer trading at a low single-digit trailing multiple where a formerly cautious firm now sees a clear path back to buybacks.
Risks: further reserve strengthening if long-term-care mortality experience deteriorates; sensitivity of variable-annuity fair value to equity-market drawdowns; potential ratings action if capital deployment moves faster than statutory support allows; and slower fee-income growth in the retirement-plan-services franchise.
NRG Energy (NRG) — Siebert Williams initiates Buy at $184
NRG Energy is a Texas-based independent power producer with a competitive retail electricity franchise and a growing large-load data-center power pipeline in ERCOT and PJM. On July 6, Siebert Williams initiated coverage with a Buy rating and a $184 price target, joining an already constructive covering group. Barclays's Nicholas Campanella holds Overweight $200, Jefferies's Julien Dumoulin-Smith at Buy $181, Wells Fargo's Shahriar Pourreza at Overweight $206, UBS's William Appicelli at Buy $211, and Seaport Global's Angie Storozynski at Buy $202.
Shares closed at $141.01 on July 6, up 3.15%, with a market cap of $29.8 billion and a trailing P/E of 20.32. The 52-week range is $120.11 to $189.96. The consensus rating is Buy, with 5 of 7 analysts bullish, an average target of $192.71, a median of $200, a high of $211, and a low of $154. The framing is an AI-power beneficiary trading roughly 26% below its 52-week high where fresh coverage has picked up the bullish thread.
Risks: ERCOT power-price volatility; execution risk on large data-center deal signings and interconnection queues; regulatory and reliability rulings from ERCOT and PUCT; and the leveraged capital structure inherited from prior acquisitions.
Glaukos (GKOS) — H.C. Wainwright picks up coverage at Buy on eye-care pipeline
Glaukos develops minimally invasive glaucoma and corneal-health devices, with iDose TR positioned as the first sustained-release drug delivery platform inside the eye. On July 6, H.C. Wainwright initiated coverage with a Buy rating and a $168 price target, marking one of the highest targets on the Street. Piper Sandler's Adam Maeder holds Overweight $165, Citigroup's Joanne Wuensch at Buy $162, Wells Fargo's Larry Biegelsen at Overweight $138, Needham's David Saxon at Buy $150, and BTIG's Ryan Zimmerman at Buy $162.
Shares closed at $148.70 on July 6, up 0.24%, with a market cap of $8.7 billion. The company is still investing ahead of iDose TR scaling, so a trailing P/E is not meaningful. The 52-week range is $73.16 to $150.26. The consensus rating is Strong Buy, with 8 of 8 analysts bullish, an average target of $152.75, a median of $155, a high of $165, and a low of $138. The framing is a medtech growth name pressing exactly on its 52-week high as unanimous coverage adds a fresh $168 target.
Risks: iDose TR reimbursement and coverage timelines remain a variable across payers; competition from AbbVie's Durysta and other sustained-release entrants; corneal-health commercialization execution; and equity-market sensitivity given the elevated growth multiple.
Found this helpful? Share it with others.